<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F7963F0F-F1A1-4A44-A563-A29028086C5B"><gtr:id>F7963F0F-F1A1-4A44-A563-A29028086C5B</gtr:id><gtr:name>Ingenza Ltd</gtr:name><gtr:address><gtr:line1>Wallace Building</gtr:line1><gtr:line2>Roslin Biocentre</gtr:line2><gtr:line3>Roslin</gtr:line3><gtr:line4>Midlothian</gtr:line4><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F7963F0F-F1A1-4A44-A563-A29028086C5B"><gtr:id>F7963F0F-F1A1-4A44-A563-A29028086C5B</gtr:id><gtr:name>Ingenza Ltd</gtr:name><gtr:address><gtr:line1>Wallace Building</gtr:line1><gtr:line2>Roslin Biocentre</gtr:line2><gtr:line3>Roslin</gtr:line3><gtr:line4>Midlothian</gtr:line4><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/81EDBB09-1DD7-41D5-8A5C-BE1ACE4591F8"><gtr:id>81EDBB09-1DD7-41D5-8A5C-BE1ACE4591F8</gtr:id><gtr:firstName>Mathew</gtr:firstName><gtr:surname>Upton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EB954824-3D70-4D6E-B98B-E2C323E12AAF"><gtr:id>EB954824-3D70-4D6E-B98B-E2C323E12AAF</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Warn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0EC21C0F-9C2B-4F26-BDEA-172DC8C9171A"><gtr:id>0EC21C0F-9C2B-4F26-BDEA-172DC8C9171A</gtr:id><gtr:firstName>Jeremy Paul</gtr:firstName><gtr:surname>Derrick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FJ021474%2F1"><gtr:id>C76ECCF1-CE6F-48F8-A11B-E287C3E138B6</gtr:id><gtr:title>Development of epidermicin NI01 for nasal decolonization</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/J021474/1</gtr:grantReference><gtr:abstractText>The World Health Organisation have stated that infections caused by antibiotic resistant bacteria (e.g. MRSA) are one of the greatest current threats to public health and there is an urgent need for novel antibiotics to combat drug resistant infections. We have discovered epidermicin, an exciting and important new antibiotic that rapidly kills MRSA and other bacteria. The new antibiotic is more active than current antibiotics, is non-toxic and bacteria don't develop resistance to it. These are significant advantages over current antibiotics so we plan to develop epidermicin for clinical use. People who carry MRSA in the nose have a high risk of developing infection and transmitting MRSA, so we will examine how effective epidermicin is for removing MRSA from the nose. We will also carry out experiments designed to help us to understand how epidermicin kills bacteria and why they do not become resistant and carry out work to ensure that the antibiotic is not toxic when used clinically.</gtr:abstractText><gtr:fund><gtr:end>2014-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>132496</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ingenza Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Development of expression system for commercial scale production</gtr:description><gtr:id>D060398D-3B73-4DED-B24B-BAE1A0A3E259</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Ingenza are bringing 14 years of IB expertise to the project to maximise the chance of successfully achieving our target level of expression</gtr:partnerContribution><gtr:piContribution>Ingenza have partnered with us to develop the recombinant expression system for production of epidermicin and related peptides. This work is now supported by a TSB/Innovate UK IBC award (starting April 2015).

My research team will be evaluating the peptides that are produced in the Ingenza expression pipeline.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Mode of action work with Leeds University</gtr:description><gtr:id>CCD56C9B-1935-49BA-B869-6B97008A495F</gtr:id><gtr:impact>Poster presentation at ICAAC, 2013. This work is being written up into a manuscript for submission in the near future</gtr:impact><gtr:partnerContribution>Investigated the mode of action using liposomes and in house strains of bacteria to indicate cell wall activity of peptide. Also mapped the cellular response at the level of macromolecular synthesis</gtr:partnerContribution><gtr:piContribution>Peptide supplied to Alex O'Neill who worked with Post-doc on project and his own PhD student to investigate the mode of action</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>85000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Innovate UK</gtr:department><gtr:description>Capital equipment for AMR research</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Government of the UK</gtr:fundingOrg><gtr:fundingRef>86184-540263</gtr:fundingRef><gtr:id>50D6C6FC-9C5D-4A84-98BD-99381801C70A</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>417092</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial Biotechnology Catalyst - Industry Research award</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:fundingRef>44921-302214</gtr:fundingRef><gtr:id>13E1537B-F1C6-4A7E-B64C-BA98D028E528</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Findings from this work have been communicated to audiences in the general public (science in the news event and University of the 3rd Age meetings and in various local and national media outlets. The findings have been well received and generated interest in these settings.</gtr:description><gtr:id>2DD13B0D-4E2E-4AFB-AF59-C00917A5F2BC</gtr:id><gtr:impactTypes/><gtr:sector>Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention provides novel antimicrobial peptides and nucleic acids encoding them, the peptides having an inhibitory or bactericidal/bacteriostatic effect on both Gram- negative and Gram-positive bacteria. The invention includes methods of treating bacterial infections and preventing the spread of the infections or contamination by the infection. The peptides of the present invention are of particular use as therapeutics to treat Gram- negative infections and are of use in impregnation, covering or coating medical devices or implants or prosthetics prior to introduction into a patient's body</gtr:description><gtr:id>C6829525-12F7-48BF-B5B9-BABD32729E65</gtr:id><gtr:impact>None yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2015132572</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>NOVEL ANTIMICROBIAL PEPTIDES</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Demonstrated in a relevant model that epidermicin is better than the current therapy for preventing infection with methicillin resistant S aureus (MRSA), on of the most important pathogens seen in healthcare settings.
Determined the structure of epidermicin.
Identified novel data that supported submission (March 2014) of a second patent application protecting the technology being developed.</gtr:description><gtr:exploitationPathways>In vivo data justify further development through the pre-clinical pathway towards nasal decolonisation, to prepare epidermicin for use in a Phase I clinical trial</gtr:exploitationPathways><gtr:id>5088834C-EA03-4216-A468-01CE01F86394</gtr:id><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Pre-clinical development of epidermicin towards use in nasal decolonisation for MRSA carriage - during the FoF project we obtained excellent in vivo data in a murine model relevant to the selected clinical indication. This has supported further funding applications to facilitate development of epidermicin towards clinical trials</gtr:description><gtr:id>2CEDA24F-ADCC-41B2-9C82-6C613442773D</gtr:id><gtr:impact>We solved the crystal structure of epidermicin. This will inform future development and inform our efforts to understand the mode of action.</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Epidermicin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BD1BE461-F33F-4740-8809-2461726DDCDE"><gtr:id>BD1BE461-F33F-4740-8809-2461726DDCDE</gtr:id><gtr:title>Dual transcriptional-translational cascade permits cellular level tuneable expression control.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7d1d07af39adeceda3a6e1b6a6c44e36"><gtr:id>7d1d07af39adeceda3a6e1b6a6c44e36</gtr:id><gtr:otherNames>Morra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0EBCBAFD-F3E3-4C81-9D82-039EA1852E79"><gtr:id>0EBCBAFD-F3E3-4C81-9D82-039EA1852E79</gtr:id><gtr:title>A single dose of epidermicin NI01 is sufficient to eradicate MRSA from the nares of cotton rats.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fc6f88c5c726512b469004ab2a250b0"><gtr:id>3fc6f88c5c726512b469004ab2a250b0</gtr:id><gtr:otherNames>Halliwell S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/J021474/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>